CA2199954A1 - Microparticules sechees par pulverisation utilisees comme excipient therapeutique - Google Patents

Microparticules sechees par pulverisation utilisees comme excipient therapeutique

Info

Publication number
CA2199954A1
CA2199954A1 CA002199954A CA2199954A CA2199954A1 CA 2199954 A1 CA2199954 A1 CA 2199954A1 CA 002199954 A CA002199954 A CA 002199954A CA 2199954 A CA2199954 A CA 2199954A CA 2199954 A1 CA2199954 A1 CA 2199954A1
Authority
CA
Canada
Prior art keywords
microparticles
microparticles according
water
soluble material
microcapsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002199954A
Other languages
English (en)
Inventor
Andrew Derek Sutton
Richard Alan Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Holdings Cambridge Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2199954A1 publication Critical patent/CA2199954A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Abstract

L'invention concerne des microparticules d'un produit hydrosoluble, lisses et de forme sphérique, dont au moins 90 % ont une granulométrie moyenne en masse de 1 à 10 µm et qui soit comportent un agent thérapeutique ou diagnostique, soit utilisent cet agent comme produit hydrosoluble. Ces microparticules peuvent être employées avec succès dans des inhalateurs à poudre sèche pour délivrer ledit agent.
CA002199954A 1994-09-29 1995-09-26 Microparticules sechees par pulverisation utilisees comme excipient therapeutique Abandoned CA2199954A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94307126.6 1994-09-20
EP94307126 1994-09-29

Publications (1)

Publication Number Publication Date
CA2199954A1 true CA2199954A1 (fr) 1996-04-04

Family

ID=8217866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002199954A Abandoned CA2199954A1 (fr) 1994-09-29 1995-09-26 Microparticules sechees par pulverisation utilisees comme excipient therapeutique

Country Status (16)

Country Link
EP (1) EP0783298A1 (fr)
JP (1) JPH10506406A (fr)
KR (1) KR970705979A (fr)
AU (1) AU701440B2 (fr)
BR (1) BR9509171A (fr)
CA (1) CA2199954A1 (fr)
CZ (1) CZ92497A3 (fr)
FI (1) FI971332A0 (fr)
HU (1) HUT77373A (fr)
MX (1) MX9702357A (fr)
NO (1) NO971438L (fr)
NZ (1) NZ292980A (fr)
PL (1) PL319600A1 (fr)
RU (1) RU2147226C1 (fr)
WO (1) WO1996009814A1 (fr)
ZA (1) ZA958239B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827205B2 (en) 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
GB9607035D0 (en) * 1996-04-03 1996-06-05 Andaris Ltd Spray-dried microparticles as therapeutic vehicles
EP0914096B1 (fr) * 1996-05-17 2003-08-13 Elan Drug Delivery Limited Microparticules et utilisation de ces dernieres pour soigner des plaies
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
GB9615435D0 (en) 1996-07-23 1996-09-04 Andaris Ltd Spray-dried product and its therapeutic use
GB9621825D0 (en) * 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
EP0949932A1 (fr) * 1996-10-19 1999-10-20 Quadrant Healthcare (UK) Limited Utilisation de microcapsules creuses a des fins diagnostiques et therapeutiques
AU6014098A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
EP1498115A1 (fr) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Préparation de particules pour inhalation
JP3884484B2 (ja) * 1997-01-16 2007-02-21 マサチューセッツ インスティチュート オブ テクノロジー 吸入用粒子の調製
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
ATE248583T1 (de) * 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
CA2320219A1 (fr) * 1998-02-20 1999-08-26 Quadrant Healthcare (Uk) Limited Produits contenant du fibrinogene pour une utilisation therapeutique
DE69907456T2 (de) * 1998-06-24 2004-03-25 Advanced Inhalation Research, Inc., Cambridge Grosse poröse partikel ausgestossen von einem inhalator
EP1273290A1 (fr) * 1998-06-24 2003-01-08 Advanced Inhalation Research, Inc. Particules poreuses de grande taille émises par inhalateur
EP1169065B1 (fr) * 1999-04-21 2005-03-02 1355540 Ontario Inc. Formulations a base de methacoline ou d'histamine pour detecter l'asthme
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
CA2395129C (fr) 1999-12-20 2008-12-16 Nicholas J. Kerkhof Procede de production de particules d'echelle nanometrique par sechage par atomisation en lit fluidise
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001264789A1 (en) * 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
DE60127175T2 (de) * 2000-12-21 2007-11-08 Nektar Therapeutics, San Carlos Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor
GB0111420D0 (en) * 2001-05-10 2001-07-04 Biovector Solutions Ltd Soluble polymer systems for drug delivery
AU2002342241B2 (en) 2001-11-01 2007-07-19 Novartis Ag Spray drying methods and compositions thereof
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2003299795A1 (en) 2002-12-20 2004-07-22 Xeris Pharmaceuticals, Inc. Intracutaneous injection
EP1635786A2 (fr) * 2003-05-28 2006-03-22 Nektar Therapeutics Sechage par pulverisation d'une solution aqueuse alcoolique pour la fabrication d'une microparticule contenant un principe actif insoluble dans l'eau et ayant un enrobage partiel ou complet comprenant un acide amine ou un phospholipide
US8075919B2 (en) 2003-07-18 2011-12-13 Baxter International Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
CA2702340C (fr) 2006-10-12 2014-12-16 The University Of Queensland Compositions et procedes destines a moduler des reponses immunes
EP2050437A1 (fr) * 2007-10-15 2009-04-22 Laboratoires SMB Compositions de poudre sèche pharmaceutiquement améliorées pour l'inhalation
UA90013C2 (ru) * 2008-03-19 2010-03-25 Давид Анатолійович Нога Фармацевтическая композиция, содержащая инсулин, и способ его получения
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
US10004790B2 (en) 2008-09-29 2018-06-26 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
WO2010037142A1 (fr) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Materiau bioactif d'encapsulation de nanospheres et procede de preparation de nanospheres
US11524058B2 (en) 2008-09-29 2022-12-13 The Corporation Of Mercer University Oral dissolving films containing microencapsulated vaccines and methods of making same
EP2216054A1 (fr) 2009-02-06 2010-08-11 ProFibrix BV Support extravasculaire biodégradable
GB0909131D0 (en) 2009-05-28 2009-07-01 Quadrant Drug Delivery Ltd Dry powder fibrin sealant
GB0909136D0 (en) 2009-05-28 2009-07-01 Profibrix Bv Dry powder composition
CN102448443A (zh) * 2009-05-28 2012-05-09 普罗菲布瑞克斯公司 干粉纤维蛋白密封剂
WO2011005756A1 (fr) 2009-07-06 2011-01-13 Puretech Ventures, Llc Administration d'agents ciblés contre des niches de microbiote
KR20120125465A (ko) 2010-01-08 2012-11-15 프로피브릭스 비.브이. 건조 분말 피브린 실란트
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
WO2012058715A1 (fr) 2010-11-01 2012-05-10 University Of Technology, Sydney Agents immuno-modulateurs et leurs utilisations
EP3225235B1 (fr) 2011-03-10 2020-12-16 Xeris Pharmaceuticals, Inc. Formulations stables pour injection parentérale de médicaments peptidiques
WO2012122535A2 (fr) 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Formulations stables pour injection parentérale de médicaments peptidiques
RU2013155713A (ru) 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран
US9138479B2 (en) 2011-10-31 2015-09-22 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
WO2013153146A1 (fr) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Particules agrégées
IN2014DN10714A (fr) * 2012-06-26 2015-09-04 Ge Healthcare As
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
ES2752021T3 (es) 2013-02-01 2020-04-02 Glialogix Inc Composiciones y métodos para el tratamiento de enfermedades neurodegenerativas y otras enfermedades
WO2014124096A1 (fr) 2013-02-06 2014-08-14 Perosphere Inc. Formulations de glucagon stables
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
CN113768881A (zh) 2013-10-08 2021-12-10 人工智能治疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
PL3125875T3 (pl) 2014-04-04 2023-11-20 AI Therapeutics, Inc. Nadający się do inhalacji preparat rapamycyny do leczenia stanów związanych z wiekiem
EP3149049B1 (fr) 2014-05-27 2022-10-26 The University Of Queensland Il-22 pour utilisation dans le traitement des maladies métaboliques
CN106573106B (zh) 2014-08-06 2021-06-22 Xeris药物公司 用于皮内和/或皮下注射糊剂的注射器、试剂盒和方法
KR20170095807A (ko) 2014-10-07 2017-08-23 램 테라퓨틱스, 인코포레이티드 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
WO2016196976A1 (fr) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Appareils d'administration de glucagon et procédés associés
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2016201248A1 (fr) 2015-06-10 2016-12-15 Xeris Pharmaceuticals, Inc. Utilisation de glucagon à faible dose
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US11628208B2 (en) 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
WO2017062463A1 (fr) 2015-10-05 2017-04-13 The Corporation Of Mercer University Matériau bioactif d'encapsulation de nanosphères et procédé de préparation de nanosphères
US20180110760A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions and methods for the treatmentof neurodegenerative and other diseases
US11020403B2 (en) 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
WO2021090214A2 (fr) * 2019-11-04 2021-05-14 Alesco S.R.L. Berbérine bertrypanosomial®, ses compositions et leur utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332240T2 (de) * 1992-06-12 2003-04-10 Teijin Ltd Ultrafeines pulver zur inhalation und dessen herstellung
ES2159524T3 (es) * 1992-06-12 2001-10-16 Teijin Ltd Preparacion farmaceutica para administrarse en el interior de las vias respiratorias.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827205B2 (en) 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant

Also Published As

Publication number Publication date
FI971332A (fi) 1997-04-01
BR9509171A (pt) 1997-09-16
AU3530295A (en) 1996-04-19
JPH10506406A (ja) 1998-06-23
WO1996009814A1 (fr) 1996-04-04
RU2147226C1 (ru) 2000-04-10
CZ92497A3 (en) 1997-08-13
KR970705979A (ko) 1997-11-03
NZ292980A (en) 1999-02-25
NO971438D0 (no) 1997-03-26
HUT77373A (hu) 1998-03-30
EP0783298A1 (fr) 1997-07-16
NO971438L (no) 1997-03-26
MX9702357A (es) 1997-06-28
ZA958239B (en) 1996-09-30
PL319600A1 (en) 1997-08-18
AU701440B2 (en) 1999-01-28
FI971332A0 (fi) 1997-04-01

Similar Documents

Publication Publication Date Title
AU701440B2 (en) Spray-dried microparticles as therapeutic vehicles
US5993805A (en) Spray-dried microparticles and their use as therapeutic vehicles
MXPA97002357A (en) Microparticles dried by aspersion as vehicles therapeuti
US6416739B1 (en) Microparticles and their therapeutic or diagnostic use
JP4416325B2 (ja) 安定な噴霧乾燥タンパク質製剤
CA2216828C (fr) Excipient pour insufflation, a liberation progressive, destine a des medicaments
US5707644A (en) Small particle compositions for intranasal drug delivery
DE69907456T2 (de) Grosse poröse partikel ausgestossen von einem inhalator
CA2277801C (fr) Preparation de particules pour inhalation
CA2060176C (fr) Compositions pharmaceutiques a petites particules
CN101090714A (zh) 通过吸入伊洛前列素和微粒制剂治疗肺动脉高血压症
JP2006503865A (ja) 吸入のための徐放性の多孔性微粒子
JP2002524535A (ja) 乾燥粉末活性薬剤肺性送達
KR20020060218A (ko) 개선된 분산성을 갖는 건조 분말 조성물
CN1164186A (zh) 用作治疗载体的经喷雾干燥的微颗粒
MXPA01002649A (en) Dry powder active agent pulmonary delivery

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued